2-Chlorodeoxyadenosine en es it fr

2-Chlorodeoxyadenosine Brand names, 2-Chlorodeoxyadenosine Analogs

2-Chlorodeoxyadenosine Brand Names Mixture

  • No information avaliable

2-Chlorodeoxyadenosine Chemical_Formula


2-Chlorodeoxyadenosine RX_link


2-Chlorodeoxyadenosine fda sheet


2-Chlorodeoxyadenosine msds (material safety sheet)

2-Chlorodeoxyadenosine MSDS

2-Chlorodeoxyadenosine Synthesis Reference

No information avaliable

2-Chlorodeoxyadenosine Molecular Weight

285.687 g/mol

2-Chlorodeoxyadenosine Melting Point

215 oC

2-Chlorodeoxyadenosine H2O Solubility

No information avaliable

2-Chlorodeoxyadenosine State


2-Chlorodeoxyadenosine LogP


2-Chlorodeoxyadenosine Dosage Forms


2-Chlorodeoxyadenosine Indication

For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.

2-Chlorodeoxyadenosine Pharmacology

Cladribine is a synthetic antineoplastic agent with immunosuppressive effects. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites. Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply.

2-Chlorodeoxyadenosine Absorption

Oral bioavailability is 34 to 48%.

2-Chlorodeoxyadenosine side effects and Toxicity

Symptoms of overdose include irreversible neurologic toxicity (paraparesis/quadriparesis), acute nephrotoxicity, and severe bone marrow suppression resulting in neutropenia, anemia and thrombocytopenia.

2-Chlorodeoxyadenosine Patient Information

LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/ therapies.

2-Chlorodeoxyadenosine Organisms Affected

Humans and other mammals